Antioxidant Systems, Thioredoxin and DJ-1: Novel Therapeutic Targets in Multiple Myeloma
Author(s)
Primary Supervisor
Tonissen, Kathryn
Di Trapani, Giovanna
Year published
2017
Metadata
Show full item recordAbstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by an accumulation of malignant clonal plasma cells in the bone marrow (BM). In recent years, many effective anti-MM drugs have been developed including proteasome inhibitors and immunomodulators. Introduction of the proteasome inhibitor bortezomib has improved prognosis and survival in MM patients. However, upon prolonged drug treatment, myeloma cells acquire resistance to the given treatment including bortezomib, resulting in disease relapse. Studies have shown that the BM in myeloma patients is extensively hypoxic (1% O2) compared to the BM in healthy ...
View more >Multiple myeloma (MM) is a plasma cell malignancy characterized by an accumulation of malignant clonal plasma cells in the bone marrow (BM). In recent years, many effective anti-MM drugs have been developed including proteasome inhibitors and immunomodulators. Introduction of the proteasome inhibitor bortezomib has improved prognosis and survival in MM patients. However, upon prolonged drug treatment, myeloma cells acquire resistance to the given treatment including bortezomib, resulting in disease relapse. Studies have shown that the BM in myeloma patients is extensively hypoxic (1% O2) compared to the BM in healthy individuals. Hypoxia is a crucial microenvironmental factor that plays an important role in MM disease progression and drug resistance. Due to the development of drug resistance, MM remains an incurable disease with the median survival of only 3 to 5 years. Thus, novel therapeutic strategies are required to kill myeloma cells growing under physiological O2 conditions, including hypoxic microenvironments, and to overcome both acquired and hypoxia-induced drug resistance to improve MM patient survival and prognosis.
View less >
View more >Multiple myeloma (MM) is a plasma cell malignancy characterized by an accumulation of malignant clonal plasma cells in the bone marrow (BM). In recent years, many effective anti-MM drugs have been developed including proteasome inhibitors and immunomodulators. Introduction of the proteasome inhibitor bortezomib has improved prognosis and survival in MM patients. However, upon prolonged drug treatment, myeloma cells acquire resistance to the given treatment including bortezomib, resulting in disease relapse. Studies have shown that the BM in myeloma patients is extensively hypoxic (1% O2) compared to the BM in healthy individuals. Hypoxia is a crucial microenvironmental factor that plays an important role in MM disease progression and drug resistance. Due to the development of drug resistance, MM remains an incurable disease with the median survival of only 3 to 5 years. Thus, novel therapeutic strategies are required to kill myeloma cells growing under physiological O2 conditions, including hypoxic microenvironments, and to overcome both acquired and hypoxia-induced drug resistance to improve MM patient survival and prognosis.
View less >
Thesis Type
Thesis (PhD Doctorate)
Degree Program
Doctor of Philosophy (PhD)
School
School of Natural Sciences
Copyright Statement
The author owns the copyright in this thesis, unless stated otherwise.
Subject
Multiple myeloma
Plasma cells
Bone marrow
Proteasome inhibitors
Myeloma patients
Antioxidant systems